Medication info
Januglypta Tablets 50 mg (Sitagliptin Hydrochloride Monohydrate)

Januglypta Tablets 50 mg (Sitagliptin Hydrochloride Monohydrate)

Prescription medicationTabletOral
Ingredient · strength
Sitagliptin Hydrochloride Hydrate›56.7mg / 1 tablet
Manufacturer / importer
Shinil Pharmaceutical Co., Ltd.
Appearance
Light apricot-colored, round, double-sided, convex film-coated tablets
Packaging
PTP - 28 tablets/box [(14 tablets/PTP×2)], bottle - 30 tablets/bottle, bottle - 90 tablets/bottle
Approval status
Active

MFDS item code 202100852 · Approved 2021.01.28 · Insurance code 653806130

Summary

Main use
Improvement of glycemic control in type 2 diabetes mellitus
Who takes it
Adults
Adult dose
When used as monotherapy or combination therapy, administer 100 mg once daily; the maximum daily dose is 100 mg. This medication may be taken with or without food. When administered concomitantly with a sulfonylurea or insulin, consider reducing the dose of the sulfonylurea or insulin to reduce the risk of sulfonylurea- or insulin-induced hypoglycemia (see Precautions, 5. General precautions). Patients with renal impairment Because dose adjustment is required according to renal function, assessment of renal function is recommended before and periodically during treatment with this medication. 1. No dose adjustment is required in patients with mild renal impairment (eGFR ≥ 60 mL/min/1.73 m2 and < 90 mL/min/1.73 m2). 2. No dose adjustment is required in patients with moderate renal impairment (eGFR ≥ 45 mL/min/1.73 m2 and < 60 mL/min/1.73 m2). 3. In patients with moderate renal impairment (eGFR ≥ 30 mL/min/1.73 m2 and < 45 mL/min/1.73 m2), administer 50 mg once daily. 4. In patients with severe renal impairment (eGFR ≥ 15 mL/min/1.73 m2 and < 30 mL/min/1.73 m2) or end-stage renal disease (ESRD) requiring hemodialysis or peritoneal dialysis (eGFR < 15 mL/min/1.73 m2), administer 25 mg once daily. This medication may be administered without regard to the timing of dialysis.

Ingredients

Manufacturer
Shinil Pharmaceutical Co., Ltd.

Efficacy & effects

Improvement of glycemic control in type 2 diabetes mellitus

  • Difficulty in blood sugar control in patients with type 2 diabetes
View approved original text

This medication helps patients with type 2 diabetes control their blood sugar more effectively while following dietary and exercise regimens. It can be used alone when starting treatment, and if monotherapy is insufficient, it can be administered in combination with metformin. Additionally, it can be used as an adjunct when treatment with any one of sulfonylurea, metformin, thiazolidinedione, or insulin alone is insufficient. When combined with sulfonylurea and metformin, thiazolidinedione and metformin, or insulin and metformin, if blood sugar control is inadequate, this medication can also be combined to enhance treatment effectiveness. It is used for improving blood sugar control in various treatment situations.

How to take

Adult dose

When used as monotherapy or combination therapy, administer 100 mg once daily; the maximum daily dose is 100 mg. This medication may be taken with or without food. When administered concomitantly with a sulfonylurea or insulin, consider reducing the dose of the sulfonylurea or insulin to reduce the risk of sulfonylurea- or insulin-induced hypoglycemia (see Precautions, 5. General precautions). Patients with renal impairment Because dose adjustment is required according to renal function, assessment of renal function is recommended before and periodically during treatment with this medication. 1. No dose adjustment is required in patients with mild renal impairment (eGFR ≥ 60 mL/min/1.73 m2 and < 90 mL/min/1.73 m2). 2. No dose adjustment is required in patients with moderate renal impairment (eGFR ≥ 45 mL/min/1.73 m2 and < 60 mL/min/1.73 m2). 3. In patients with moderate renal impairment (eGFR ≥ 30 mL/min/1.73 m2 and < 45 mL/min/1.73 m2), administer 50 mg once daily. 4. In patients with severe renal impairment (eGFR ≥ 15 mL/min/1.73 m2 and < 30 mL/min/1.73 m2) or end-stage renal disease (ESRD) requiring hemodialysis or peritoneal dialysis (eGFR < 15 mL/min/1.73 m2), administer 25 mg once daily. This medication may be administered without regard to the timing of dialysis.

Precautions

This medication may cause severe hypersensitivity reactions, so if allergic symptoms or skin abnormalities occur, discontinue use immediately and consult a physician. If symptoms of pancreatitis, such as severe abdominal pain, nausea, or vomiting occur while taking this medication, inform medical personnel immediately, and if pancreatitis is suspected, discontinue use of this drug. Patients with type 1 diabetes or diabetic ketoacidosis should not use this medication, and it should not be administered to individuals who are allergic to this drug or its components. Patients with impaired kidney function need to adjust their dosage, so regular kidney function tests should be conducted, and the medication should be taken according to a physician's instructions. This medication can cause hypoglycemia, so when used in combination with insulin or sulfonylurea, blood sugar levels should be carefully monitored, and dose adjustments for hypoglycemic agents may be necessary. Symptoms such as headache, upper respiratory infection, nasopharyngitis, diarrhea, etc., may occur during treatment; consult medical personnel if the symptoms persist or worsen. This medication can be used in the elderly, but dosage adjustments and kidney function tests are essential due to possible decreased kidney function. Pregnant or breastfeeding women should avoid this medication, and safety and efficacy have not been established in children and adolescents under 18 years of age. In cases of overdose, it is necessary to remove the drug from the gastrointestinal tract and provide appropriate treatment and monitoring, such as an electrocardiogram; some may be removed by dialysis. If symptoms like joint pain, skin blisters, or rash occur during treatment, inform a doctor immediately, and if necessary, drug discontinuation and specialist evaluation may be required. Drug interactions are minimal, but caution is advised when taken with cyclosporine or digoxin, and consultation with a physician is recommended before taking them.

Side effects

  • Anaphylaxis
  • angioedema
  • Stevens-Johnson syndrome
  • acute pancreatitis
  • hypoglycemia
  • nasopharyngitis
  • upper respiratory tract infection
  • headache
  • diarrhea
  • abdominal pain
Show 31 more
  • nausea
  • peripheral edema
  • constipation
  • vomiting
  • severe and disabling arthralgia
  • vesicular pemphigoid
  • myalgia
  • limb pain
  • back pain
  • interstitial lung disease
  • pruritus
  • thrombocytopenia
  • rhabdomyolysis
  • elevated liver enzymes
  • acute renal failure
  • rash
  • urticaria
  • leukocytoclastic vasculitis
  • dyspepsia
  • dizziness
  • increased blood triglycerides
  • gastritis
  • pneumonia
  • diabetic complications
  • metabolic acidosis
  • falls
  • cardiac arrest
  • weight loss
  • hypertension
  • hypernatremia
  • erectile dysfunction

Not everyone experiences these, and they can vary from person to person.

Storage

Store this medication in a tightly closed container that is well-ventilated. It is important to maintain a storage temperature between 1°C and 30°C room temperature. Proper storage will help preserve the effectiveness of the medication for a longer period.

Appearance and packaging

Appearance

Light apricot-colored, round, double-sided, convex film-coated tablets

Package unit

PTP - 28 tablets/box [(14 tablets/PTP×2)], bottle - 30 tablets/bottle, bottle - 90 tablets/bottle

Same-ingredient medicines

Even with the same ingredient, strength, dosage form and how it is taken can differ.

Even with the same ingredient, the dose and directions can differ by strength and dosage form. Talk to a doctor or pharmacist before switching from a medication you are already taking.

Questions about this medicine

No questions yet.

For anything that needs medical judgment, consult a doctor or pharmacist.

Related searches

Search tags

Suggested searches

This drug information is based on data provided by the Korea Ministry of Food and Drug Safety.
Consult a doctor or pharmacist for accurate dosage, administration, and usage instructions.